- 中文名称
ABT-869 (50 mg)
- 英文名字
- Linifanib, ABT-869, N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N
- 供应商
- Cayman
- 产品货号
- 13653-50
- 产品报价
- ￥29890/50 mg
- 产品说明书
- 点击查看
- 购买方式
- 产品新闻
- 背景资料
- Receptor tyrosine kinases -RTKs) mediate critical signaling transduction pathways important for cell survival, growth, and differentiation. Whereas aberrant tyrosine kinase signaling is correlated with the progression of various cancers, RTK inhibitors are useful as cancer therapy agents. ABT-869 is an ATP-competitive, multi-targeted RTK inhibitor that is completely effective against all members of the vascular endothelial growth factor -VEGF) and platelet derived growth factor -PDGF) receptor families -e.g., KDR, Flt1, Flt3, Flt4, CSF-1R, and KIT) demonstrating IC50 values ranging from 4-190 nM. ABT-869 shows little activity against unrelated RTKs, cytoplasmic tyrosine kinases, or Ser/Thr kinases -IC50s > 1 uM). ABT-869 inhibits proliferation in MV-4-11 and MOLM-13 cells -acute myeloid leukemia cell lines harboring RTK mutations; IC50s = 4 and 6 nM, respectively), inducing apoptosis as evidenced by an increased sub-G0/G1 phase cell population, caspase activation, and PARP cleavage. In murine xenograft models, as well as in a phase 1 clinical trial, ABT-869 demonstrated respectable efficacy in solid tumors including lung and hepatocellular carcinomas.
- 产品描述
- An ATP-compeitive, multi-targeted RTK inhibitor that inhibits all members of the VEGF and PDGF receptor families -IC50s = 4-190 nM); inhibits proliferation in MV-4-11 and MOLM-13 cells -IC50s = 4 and 6 nM, respectively)
- 产品形式
- 保存建议
- -20
- 其他
- Cayman Chemical
- 注意
-
该页面的中文产品信息的翻译，仅供参考。准确的产品信息请以厂家的英文说明书为准。下单前，请浏览说明书确认。
-
